Bupranolol
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral, topical (eye drops) |
ATC code | |
Pharmacokinetic data | |
Bioavailability | < 10% |
Protein binding | 76% |
Metabolism | First pass elimination > 90% |
Elimination half-life | 2-4 hours (plasma) |
Excretion | > 88% renal (as carboxybupranolol) |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to propranolol.
Uses and dosage
Like other beta blockers, oral bupranolol can be used to treat hypertension and tachycardia.[citation needed] The initial dose is 50 mg two times a day. It can be increased to 100 mg four times a day. Bupranolol eye drops (0.05%-0.5%) are used against glaucoma.[citation needed]
Pharmacology
Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo
carboxyl group –, of which 88% are eliminated renally within 24 hours.[citation needed
]
Adverse effects, contraindications, interactions
Adverse effects, contraindications and interactions are similar to other beta blockers.[citation needed]
References
Further reading
- Dinnendahl V, Fricke U (2007). Arzneistoff-Profile (in German). Vol. 2 (21 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.